CorDx Tyfast Flu A/B & COVID-19 At Home Multiplex Rapid Test; CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test
CorDx, Inc. · Decision date Oct 14, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-14 for K262432, submitted by CorDx, Inc. of Alpharetta, Georgia, under product code SCA and the Microbiology specialty. The listed device names are the CorDx Tyfast Flu A/B & COVID-19 At Home Multiplex Rapid Test and the CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test, classified as a multi-analyte respiratory virus antigen detection test. The application was received 07/16/2026 and reviewed as a traditional 510(k) without third-party review, combination product status or an authorized predetermined change control plan.
A separate CLIA database entry, document CR260530 tied to K262432, lists both named tests with anterior nasal swab sampling as waived for SARS-CoV-2 and other respiratory viruses in virology, effective 10/20/2026. That waiver record is distinct from the 510(k) clearance itself. The source material does not include the decision summary, so the specific components, changed items, analytical or clinical performance data and any labeling limitations remain unknown and are not characterized here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 14, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262432
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- CorDx, Inc.
- Product code
- SCA
- Decision code
- SESE
- Decision date
- Oct 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-Analyte Respiratory Virus Antigen Detection Test.
- Applicant
- CorDx, Inc.
- Product code
- SCA
- FDA device class
- 2
FDA decision timeline
K262432 received
Application receipt date recorded by FDA.
K262432 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CorDx, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Alpharetta, GA
Sources and methodology
- Original FDA record: K262432
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records